53799-14-7

Basic information

• Product Name: 4-((3r,5r,7r)-adamantan-1-yl)-2-methylphenol
• Synonyms: 4-((3r,5r,7r)-adamantan-1-yl)-2-methylphenol
• CAS NO: 53799-14-7
• Molecular Weight: 242.361
• Mol File: 53799-14-7.mol

Chemical Properties

• CAS DataBase Reference: 4-((3r,5r,7r)-adamantan-1-yl)-2-methylphenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((3r,5r,7r)-adamantan-1-yl)-2-methylphenol(53799-14-7)
• EPA Substance Registry System: 4-((3r,5r,7r)-adamantan-1-yl)-2-methylphenol(53799-14-7)

Safety Data

• Hazardous Substances Data: 53799-14-7(Hazardous Substances Data)

Upstream product

• 935-56-8 1-chloroadamantane 
• 95-48-7 ortho-cresol 
• 768-90-1 1-Adamantyl bromide 
• 578-58-5 2-methylmethoxybenzene 
• 1414335-36-6 1-(4-methoxy-3-methyl-phenyl)-adamantane 

Downstream Products

• 56432-65-6 2-Methyl-4-(1-adamantyl)-cyclohexanol 
• 1373443-06-1 (E)-3-(3-(4-adamantan-1-yl-2-methylphenoxy)acrylamido)benzoic acid methylester 
• 1373443-29-8 (E)-3-(4-adamantan-1-yl-2-methylphenoxy)acrylic acid methyl ester 
• 1429054-32-9 2-(4-(adamantan-1-yl)-2-methylphenoxy)acetic acid 

Relevant articles and documents

Alkylation of aromatic compounds with 1-bromoadamantane in the presence of metal complex catalysts

Synthesis of aryladamantanes was performed by reaction of 1-bromoadamantane with aromatic compounds in the presence of metal complex catalysts containing Mo, Cr, W, Cu, and Co.

Phenoxyacrylic derivatives and use thereof

The present invention relates to a phenoxyacrylic derivative and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a nonalcoholic fatty liver disease. The compound according to the present invention has an

NOVEL COMPOUNDS AS HIF-1ALPHAINHIBITORS AND MANUFACTURING PROCESS THEREOF

The present invention relates to novel compounds as HIF-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1α-mediated VEGFA expression.

NOVEL COMPOUNDS AS HIF-1αINHIBITORS AND MANUFACTURING PROCESS THEREOF

The present invention relates to novel compounds as HIF-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1α-mediated VEGFA expression.

Synthesis and structure-activity relationship of (E)-phenoxyacrylic amide derivatives as Hypoxia-Inducible Factor (HIF) 1α inhibitors

A series of (E)-phenoxyacrylic amide derivatives were synthesized and evaluated as hypoxia inducible factor (HIF) 1α inhibitors. The present structure-activity relationship study on this series identified the morpholinoethyl containing ester 4p as a potent inhibitor of HIF-1α under hypoxic conditions (IC50 = 0.12 μM in a cell-based HRE reporter assay) in HCT116 cells. The representative compound 4p suppressed hypoxia-induced HIF-1α accumulation and targeted gene expression in a dose-dependent manner. The effect of HIF-1α inhibition by 4p was further demonstrated by its inhibitory activity on in vitro tube formation and migration of cells, which may be valuable for development of novel therapeutics for cancer and tumor angiogenesis.